The addition of zoledronate to tumor-associated antigen (TAA)-loaded dendritic cells (DCs) promotes the activation of interferon γ-secreting Vγ9 γδ T cells, in turn eliciting TAA-specific CD8+ T-cell responses. Immunological responses induced by zoledronate-pulsed DC-based vaccines have been associated with therapeutic effects in clinical trials.
Keywords: Wilms’ tumor 1; dendritic cell; electroporation; intratumoral injection; tumor-associated antigen-derived peptide; zoledronate.